WPWayan Agus Surya Pradnyana

Wayan Agus Surya Pradnyana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wayan Agus Surya Pradnyana has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Gusti Ngurah Prana Jagannatha

    Department of Cardiology and Vascular Medicine Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital Denpasar Bali Indonesia

    7 shared publications
  • Stanly Kamardi

    Faculty of Medicine, Udayana University, Denpasar-Bali, Indonesia

    4 shared publications
  • Aa Ayu Dwi Adelia Yasmin

    Department of Cardiology and Vascular Medicine, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia

    3 shared publications
  • A.A.A.D.A. Yasmin

    Department of Cardiology and Vascular Medicine, Sanglah General Hospital, Udayana University, Denpasar, Bali, Indonesia

    1 shared publication
  • A.K. Umam

    Bachelor of Medicine and Medical Profession Study, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia

    1 shared publication
  • A.T.D. Putri

    Bachelor of Medicine and Medical Profession Study, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia

    1 shared publication

Latest Publications

  • Open Access

    Maternal-related factors associated with development and improvement of peripartum cardiomyopathy and therapeutic outcomes of bromocriptine

    by I Gusti Bagus Mulia Agung Pradnyaandara, Ryan Saktika Mulyana, Jane Carissa Sutedja, Gusti Ngurah Prana Jagannatha, I Bagus Satriya Wibawa, Fanny Deantri, I Wayan Agus Surya Pradnyana, Bryan Gervais De Liyis

    HIGHLIGHTS Younger age, black race, normotension, and multiparity indicate a poorer prognosis for peripartum cardiomyopathy recovery, while bromocriptine therapy reduces adverse events. ABSTRACT Objectives: This study aimed to fill the significant knowledge gap regarding peripartum cardiomyopathy (PPCM), a heart failure phenotype linked to pregnancy. The main objectives were to explore the factors influencing the development and progression of PPCM and to assess the outcomes of bromocriptine.Materials and Methods: Systematic search across PubMed, ScienceDirect, and Cochrane Library identified studies until December 2022. This study includes non-randomized prospective and retrospective studies, as well as relevant randomized controlled trials. Risk factors were compared between the recovered and non-recovered PPCM groups, and bromocriptine therapy outcomes were evaluated against standard heart failure treatment as the primary endpoint.Results: The analysis included 24 observational studies and 1 randomized controlled trial involving 1,651 PPCM patients; 9 studies evaluating the outcomes of bromocriptine therapy. The most prevalent factors were caesarean delivery (proportion=53%, 95%CI=41%-66%) and anemia (proportion=51%, 95%CI=38%-65%). Non-recovered patients were younger (MD=-1.04 years old, 95%CI=-1.82-(-0.27), p=0.008) and predominantly black (RR=1.82, 95%CI=1.43-2.31, p <0.001). Hypertensive disorders and primiparity were found less among non-recovered patients (RR=0.73, 95%CI=0.60-0.88, p=0.001; RR=0.81, 95%CI=0.66-0.99, p=0.04, respectively). Non-recovered patients also exhibited higher baseline serum creatinine levels, lower LVEF, larger left ventricular end-systolic diameter (LVESD), larger left ventricular end-diastolic diameter (LVEDD), and lower fractional shortening (all P-values<0.05). Furthermore, bromocriptine significantly reduced major adverse cardiac events (MACE), mortality, and increased LVEF (all P-values<0.05).Conclusion: Younger maternal age, black race, absence of hypertension, and multiparity are associated with poorer prognosis for PPCM recovery. Bromocriptine therapy demonstrates superior benefits in reducing adverse events in PPCM.


  • Open Access

    The role of antihypertensive drugs in patients with preeclampsia and how to prevent it

    by I Gde Sastra Winata, I Wayan Agus Surya Pradnyana, Maria Septiana Parmonang Aroean

    HIGHLIGHTS 1. Preeclampsia, or hypertension in pregnancy, remains a serious problem that has negative short and long-term consequences for the mother and the baby. 2. The use of antihypertensive medications has its own precautions as it they may harm the fetus. 3. Prophylactic measures with minimal or moderate impact may be beneficial for mothers with hypertension in pregnancy. ABSTRACT Treatment of hypertension in pregnancy, such as preeclampsia (PE), is still a difficult issue with negative short and long-term consequences for both the mother and the baby. Screening for preeclampsia at 11-13 weeks' gestation using a combination of maternal demographic characteristics and medical history with biomarker measurements can identify approximately 75% of women who develop premature preeclampsia with delivery at 37 weeks gestation and 90% of those with early preeclampsia. Preeclampsia has a 10% positive screen rate at 32 weeks. Another important worry on the use of antihypertensive medications during pregnancy is the potential harm to the fetus. Methyldopa, hydralazine, labetalol, and nifedipine are some common antihypertensive medications. Aspirin use is frequently related to a decrease in the prevention of early preeclampsia, but it must be accompanied by medication adherence. Aspirin can be coupled with heparin. Recent investigations on the use of furosemide and nifedipine in preeclampsia have also revealed a new combination.

  • Open Access

    C-Reactive Protein to Albumin Ratio Predict In-Hospital and Long-term Outcome of ST-Segment-Elevation Myocardial Infarction Patients with SARS-CoV2 Infection Underwent Fibrinolytic Therapy.

    by Gusti Ngurah Prana Jagannatha, I Made Junior Rina Artha, I Wayan Agus Surya Pradnyana, Stanly Kamardi

    Background: The choice of reperfusion therapy in STEMI patients with COVID-19 is unclear. CRP to Albumin ratio (CAR) found to be a predictor of thrombus burden. This study was to determine the relationship and predictive value of CAR to in-hospital and long-term outcome of STEMI patients with COVID-19 treated with fibrinolytic. Methods: 297 COVID-19 patients with STEMI underwent fibrinolytic were enrolled. In-hospital outcomes were in-hospital mortality due to cardiovascular death which was divided into mortality 48 hours, fibrinolytic failure, and cardiogenic shock. The presence of reinfarction post fibrinolytic and mortality after the patient discharged was assessed as the long-term outcome. Results: During follow-up, 19.8% experienced in-hospital mortality and 16.1% had reinfarction. In the in-hospital outcome, patients with in-hospital death, failed fibrinolytic and cardiogenic shock had higher CAR (6.7+2.4 vs 4.7+1.9; 6.3+1.9 vs 2.1+1.6; 5.5+2.1vs1.8+1.5) with all p-value 4.46 can be a predictor of fibrinolytic failure with sensitivity of 86.7% and specificity of 93.6% (PR19.82; 95%CI 10.32-38.06) and predictor of in-hospital death 3.67 was also associated with higher reinfarction event (p=0.001). Conclusion: CAR has the potential to be a predictor of in-hospital and long-term outcomes for STEMI patients with COVID-19 which can help determine which patients need more invasive strategy to prevent mortality and morbidity.

  • Open Access

    33 HYPERTENSION AND PRE-EXISTING COMORBIDITIES ASSOCIATES WITH MAJOR ADVERSE CARDIAC EVENTS IN CORONARY ARTERY DISEASE PATIENTS ADMITTED TO INTENSIVE CARDIOVASCULAR CARE UNIT IN SANGLAH HOSPITAL: THE MANY FACES OF A SILENT KILLER

    by P.S. Upadhana, I.G.G. Sastrawan, A.T.D. Putri, N.L.S. Darmayanti, G.N.P. Jagannatha, A.K. Umam, I.W.A.S. Pradnyana, I.G.A.A.C Cahyarini, A.R. Wijaya, I.B.R. Wibhuti

    Background: Coronary artery disease (CAD) patients with a history of hypertension and underlying comorbidities are at high risk of developing major adverse cardiac events (MACE) and increase the mortality of the patients. Objective: This study aims to determine the association of hypertension and MACE in CAD patients admitted to ICCU. Method: This research is an analytic study with a cross-sectional approach. The data used is secondary data from the records of patients who were admitted to ICCU at Sanglah Hospital on 1 January 2021- 31 December 2021 with total sampling technique. Result: There were 376 patients included in this study. The majority of patients were male (n=291,77.4%) with the median overall patient age of 58 years old. Most of MACE found in the patients were revascularization (n=113;30.1%). The prevalence of hypertension was 19.1%. There were significant differences in length of in hemoglobin (p=0.006), lymphocytes count (p=0.002), uric acid (p=0.032) and GFR (p=0.000) in the patients classified based on MACE. MACE was significantly associated with hypertension (PR=1.285;95%CI=1.102-1.498;p=0.006). Chi-square analysis showed that stroke (PR=2.386;95%CI=1.271-4.480;p=0.007), heart failure (PR=2.533;95%CI=1.574-4.078;p=0.000), and malignant arrhythmia (PR=1.820;95%CI=1.229-2.694;p=0.004) were significantly associated with hypertension. Association of hypertension and kidney disease were significantly associated with stroke (PR= 2.386;95%CI=1.271-4.480;p=0.007), malignant arrhythmia (PR=1.820;95%CI=1.229-2.694;p=0.004) and heart failure (PR=2.533;95%CI=1.574-4.078;p=0.000). Association of hypertension and COVID-19 were also significantly associated with malignant arrhythmia (PR= 2.253;95%CI=1.309-3.877;p=0.011). Conclusion: There were significant association between hypertension with MACE in the patients. Intervention on these factors can prevent further mortality.

  • Open Access

    7 IMPACT OF DAY-TO-DAY BLOOD PRESSURE VARIABILITY TO IN-HOSPITAL MORTALITY IN PATIENTS WITH COVID-19 AND EFFICACY OF ANTIHYPERTENSIVE AGENTS

    by G.N.P. Jagannatha, I.W.A.S. Pradnyana, S. Kamardi, A.A.A.D.A. Yasmin

    Background: Blood pressure variability (BPV) plays an important role in hypertensive patients, and frequently associated with organ damage, but the impact of BPV to outcome in COVID-19 patients remain unclear. Objectives: To investigate the relationship between BPV and in-hospital mortality, hypertensive status, severity of COVID-19, and antihypertensives in patients with COVID-19. Methods: This was a cohort prospective study that enrolled 351 patients hospitalized with COVID-19. Subjects were classified according to the presence of hypertension, the severity of COVID-19, and BPV status. Mean Arterial Pressure (MAP) was measured at 6 a.m. and 6 p.m. during hospitalization, and BPV was calculated as the coefficient of variation of MAP (MAPCV). MAPCV values above the median were defined as high BPV. We compared the hypertensive status, COVID-19 severity, in-hospital mortality and antihypertensive agents between the BPV groups. Results: The mean age was 53.85±18.84 years-old. Subjects with high BPV were significantly associated with hypertension status (PR=1.38; 95%CI=1.13-1.70; p=0.003) or severe COVID-19 (PR=1.39; 95%CI=1.09-1.76; p=0.005). High BPV also significantly increased risk of mortality (HR=2.30; 95%CI=1.73-3,86; p=Conclusions: High BPV was associated with hypertensive status and severe COVID-19, and these factors together increased in-hospital mortality. CCB are antihypertensive agents that were potentially effective in suppressing BPV and mortality in COVID-19 patients.

  • Open Access

    33. CHARACTERISTICS AND COMORBIDITIES OF HYPERTENSIVE PATIENTS IN SANGLAH GENERAL HOSPITAL DURING COVID-19 PANDEMIC

    by I Wayan Agus Surya Pradnyana, Gusti Ngurah Prana Jagannatha, Stanly Kamardi, Aa Ayu Dwi Adelia Yasmin

    Background: Recent evidences suggest that hypertension is the most common underlying comorbid among COVID-19 patients, which often occurs in adults who are at higher risk of being infected with the SARS-CoV-2 virus and experiencing severe symptoms. Hypertension is also commonly accompanied by many comorbidities that will further compromised the clinical presentation of COVID-19 patients. Determination and appropriate management of hypertension and its comorbidities would be an important aspect during the pandemic Objective: The aims of this study is to define the characteristics and comorbidities among hypertensive patients in outpatient settings during pandemic era. Methods: This descriptive cross-sectional study included 108 medical records of patients with hypertension diagnosis in outpatient cardiology clinic, at Sanglah General Hospital in January 2021. Result: Among 108 subjects, there was male predominance (57.4%) with mean of age 54.07 years old. About 23.1% subjects were active smokers and 61.1% were overweight/obese. The most common comorbidities that was found on subjects was Coronary Artery Disease (50%), which was followed by heart failure (27.8%) and Diabetes Mellitus (14.8%). Blood pressure was controlled only in 39.8% patients. The patients most commonly took combination therapy (74.1%), with calcium channel blocker (CCB) was the most used pharmacotherapy (81.5%). Conclusion: Hypertension and its comorbidities were important predictors of poor outcome among COVID-19 patients. Therefore, optimal therapy and control for all risk factors during this pandemic are mandatory, regarding the benefit for morbidity and mortality.

  • Open Access

    32. HYPERTENSION AND DILATED CARDIOMYOPATHY IN PEDIATRIC PATIENT: THE ROLE OF L-CARNITINE

    by Gusti Ngurah Prana Jagannatha, Wayan Agus Surya Pradnyana, Stanly Kamardi, Aa Ayu Dwi Adelia Yasmin, Ni Putu Veny Kartika Yantie

    Background: Carnitine is an essential compound for cellular metabolism, and plays an important role in blood pressure (BP) regulation and cardiac development. Carnitine deficiency is a disorder that relate to pediatric hypertension and dilated cardiomyopathy, with possibilities of rapid reversal after carnitine replacement. Objective: This report describes a child suffering from hypertension and dilated cardiomyopathy with suspected carnitine deficiency. Case description: A 4-year-old boy came to emergency department on August 2018 with shortness of breath. BP was 140/80 mmHg, electrocardiogram revealed sinus tachycardia 150 bpm, echocardiography demonstrated stretch PFO, moderate TR, mild AR, and dilated cardiomyopathy with EF 31.14%. He was diagnosed with grade II hypertension and congestive heart failure. Antihypertensive and heart failure treatment were administered. There was no vascular disorder found, kidney function test and urinalysis were within normal limit. He was also found to have malnutrition, stunting, and suspected to suffer from carnitine deficiency, hence L-carnitine and vitamin B6 were commenced since day 16. Patient's condition was gradually improved and discharged on the 26th day. Unfortunately, he stopped L-carnitine 1 year afterwards, but still continue to take vitamin B6. The last follow-up evaluation on January 2021 showed improvement of BP control (112/70 mmHg) and reversal of cardiac dysfunction with EF 68.9%. Discussion: Carnitine deficiency is a rare but treatable cause of pediatric hypertension and cardiomyopathy. Although previous case reports showed complete improvement within a few months, however that was not happened in this case, that may be caused by L-carnitine withdrawal.

  • Open Access

    34. BLOOD PRESSURE CONTROL AMONG HYPERTENSIVE PATIENTS IN SANGLAH GENERAL HOSPITAL DURING COVID-19 PANDEMIC

    by Stanly Kamardi, Gusti Ngurah Prana Jagannatha, I Wayan Agus Surya Pradnyana, Aa Ayu Dwi Adelia Yasmin

    Background: The COVID-19 pandemic presents a challenge to control patients with chronic disease and conditions, because many people have postponed regular visit for chronic health condition such as hypertension. To make things worse, hypertension is the most important comorbidities and predictor of poor outcomes from COVID-19. Blood pressure control become more crucial to be top priority during this pandemic and beyond. Objective: The aim of this study is to determine the blood pressure control status among hypertensive patient in outpatient settings during the pandemic, as compared to before the pandemic of COVID-19. Methods: This retrospective, comparative cross-sectional study included 108 medical records of patients with hypertension diagnosis in outpatient cardiology clinic, at Sanglah General Hospital in January 2021. The data obtained were blood pressure during pandemic in January 2021, compared to blood pressure in the same patient before the pandemic (before March 2020). Result: The proportion of controlled hypertension before pandemic era was 49.1%, and has decreased during the pandemic to 39.8% (p value = 0.123). Wilcoxon signed rank test showed that there was increased systolic blood pressure level between before pandemic compared to during pandemic of COVID-19 (p value = 0.041). Conclusion: The optimal management of hypertension become a very important issue during pandemic of COVID-19, since patients with this pre-existing condition could experience severe complications when infected with SARS-CoV-2. The alternatives to hospital and community-based care, such as mobile phone consultation or telemedicine can be developed by the multidiscipline collaboration to increase control status of hypertension.